Want to see AU:RHY full AI Analyst Report?
Top Page
Rhythm Biosciences Ltd.
(Sydney:RHY)
Select Model
Select Model
Rating:45Neutral
Price Target:
AU$0.09
▼(-15.00% Downside)
Action:Reiterated
Date:08/28/26
The score is held down primarily by weak financial performance—persistent losses, unstable revenue (including a sharp FY2026 decline), and significant ongoing cash burn—partly offset by a balance sheet that is not debt-heavy. Technical indicators provide a modest near-term positive (price above 20D/50D with positive MACD), but the longer-term trend remains weak (below 100D/200D). Valuation is limited by negative earnings and no dividend support.
Positive Factors
Manageable leverage
The debt-light balance sheet provides more financial flexibility than a highly leveraged structure and reduces pressure from interest and refinancing obligations. Positive equity also gives the company a stronger capital base while it works to improve profitability and fund ongoing diagnostic development.
Negative Factors
Persistent unprofitability
Persistent losses indicate that the current business has not yet reached an economically sustainable operating scale. Continued negative EBIT, EBITDA and net income can erode the capital base over time, constrain reinvestment, and make progress toward self-funded growth dependent on a material improvement in operations.
Read all positive and negative factors
Positive Factors
Negative Factors
Manageable leverage
The debt-light balance sheet provides more financial flexibility than a highly leveraged structure and reduces pressure from interest and refinancing obligations. Positive equity also gives the company a stronger capital base while it works to improve profitability and fund ongoing diagnostic development.
Read all positive factors
Rhythm Biosciences Ltd. (RHY) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$31.67M
Dividend YieldN/A
Average Volume (3M)213.39K
Price to Earnings (P/E)―
Beta (1Y)1.07
Revenue Growth239.64%
EPS Growth-37.21%
CountryAU
Employees23
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-0.02
Shares Outstanding364,059,840
10 Day Avg. Volume185,937
30 Day Avg. Volume213,387
Financial Highlights & Ratios
PEG Ratio-0.21
Price to Book (P/B)8.36
Price to Sales (P/S)356.41
P/FCF Ratio-5.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Rhythm Biosciences Ltd. Business Overview & Revenue Model
Company Description
Rhythm Biosciences Limited functions as a forward-thinking enterprise focused on predictive cancer diagnostics, active across both Australian and global territories. The company's core operations involve the creation, advancement, and market intro...
How the Company Makes Money
null...
Rhythm Biosciences Ltd. Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
55
Neutral
Cash Flow
28
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 85.34K | 3.19M | 1.69M | 3.10M | 2.43M |
| Gross Profit | -4.40M | 2.97M | -1.36M | 2.91M | -101.48K |
| EBITDA | -7.27M | -3.53M | -8.35M | -11.11M | -11.10M |
| Net Income | -5.93M | -3.83M | -6.86M | -8.22M | -8.79M |
Balance Sheet | |||||
| Total Assets | 4.78M | 2.83M | 1.52M | 7.70M | 8.44M |
| Cash, Cash Equivalents and Short-Term Investments | 3.44M | 1.48M | 754.50K | 4.17M | 7.60M |
| Total Debt | 247.98K | 1.11M | 163.82K | 84.61K | 170.14K |
| Total Liabilities | 1.14M | 2.17M | 651.54K | 1.82M | 1.07M |
| Stockholders Equity | 3.64M | 659.89K | 867.17K | 5.87M | 7.37M |
Cash Flow | |||||
| Free Cash Flow | -5.26M | -2.94M | -6.22M | -7.06M | -6.24M |
| Operating Cash Flow | -5.23M | -2.92M | -6.14M | -6.96M | -6.21M |
| Investing Cash Flow | -22.75K | -582.96K | -82.28K | -99.12K | -27.01K |
| Financing Cash Flow | 7.22M | 4.19M | 2.80M | 3.63M | 11.85M |
Rhythm Biosciences Ltd. Technical Analysis
Negative
0.10
Price Trends
0.09
Negative
0.10
Negative
0.13
Negative
Market Momentum
>-0.01
Positive
44.21
Neutral
9.79
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:RHY, the sentiment is Negative. The current price of 0.1 is above the 20-day moving average (MA) of 0.09, above the 50-day MA of 0.09, and below the 200-day MA of 0.13, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 44.21 is Neutral, neither overbought nor oversold. The STOCH value of 9.79 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:RHY.
Rhythm Biosciences Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$94.51M | -11.57 | -35.89% | ― | 1.36% | 39.13% | |
47 Neutral | AU$18.40M | -1.30 | -35.10% | ― | -9.10% | 31.75% | |
47 Neutral | AU$40.16M | -1.62 | -75.96% | ― | -5.81% | -3.60% | |
45 Neutral | AU$31.67M | -4.69 | -205.17% | ― | 239.64% | -37.21% | |
43 Neutral | AU$28.02M | -3.73 | -881.94% | ― | 743.51% | -1.52% |
* Healthcare Sector Average
AU:RHY
Rhythm Biosciences Ltd.
0.08
>-0.01
-6.74%
AU:BDX
BCAL Diagnostics Limited
0.08
0.02
25.00%
AU:LDX
Lumos Diagnostics Holdings Ltd.
0.10
-0.06
-37.50%
AU:GSS
Genetic Signatures Ltd.
0.08
-0.20
-71.43%
AU:MAP
Microba Life Sciences Limited
0.06
-0.03
-34.88%
Rhythm Biosciences Ltd. Corporate Events
Rhythm Biosciences Adds Independent Director Maureen Baker to Board
Aug 28, 2026
Rhythm Biosciences Limited has announced the appointment of Maureen Baker as a director effective 27 August 2026, expanding the company’s board. According to the initial director’s interest notice lodged with the ASX, Baker holds no di...
Rhythm Biosciences Widens Annual Loss but Strengthens Asset Backing
Aug 27, 2026
Rhythm Biosciences reported a significantly wider loss for the year ended 30 June 2026, with after-tax loss rising 55% to $5.93 million as other income from ordinary activities fell 48% to $1.74 million. The company did not declare any dividends, ...
Rhythm Biosciences strengthens board to support global cancer diagnostics push
Aug 25, 2026
Rhythm Biosciences Ltd, a Melbourne-based cancer diagnostics company, develops blood tests such as ColoSTAT for early colorectal cancer detection and uses the geneType platform to provide multi-disease genetic risk assessments. Its solutions targe...
Rhythm Biosciences Options Lapse Trims Potential Share Pool
Aug 21, 2026
Rhythm Biosciences has reported the expiry of 375,000 unexercised options with an exercise price of $0.20 that were due to expire on 20 August 2026. The lapse of these options marginally reduces the company’s pool of potential future shares,...
Rhythm Biosciences Positions Itself as ASX Life Sciences Growth Play
Aug 5, 2026
Rhythm Biosciences has released a presentation targeted at investors and stakeholders, outlining its position as a growth-focused life sciences company on the ASX. The document emphasises that the information is general in nature, subject to ongoi...
Rhythm Biosciences Builds Momentum in ColoSTAT Rollout and Global Partnerships
Jul 29, 2026
Rhythm Biosciences reported solid progress in the June quarter, underpinned by a strengthened balance sheet after underwriting about $5.2 million of options to fund ongoing commercial execution. The company is accelerating the rollout of its ColoS...
Rhythm Biosciences Targets GPs With ColoSTAT Campaign After Market Research
Jul 1, 2026
Rhythm Biosciences has completed in-field market research with general practitioners, gastroenterologists, and surgeons across New South Wales, Queensland, and Victoria, confirming strong product-market fit for its ColoSTAT blood-based colorectal ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.